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Abstract 
Objective: To evaluate correlation between glycated 
haemoglobin and dyslipidaemias in patients with type-2 
Diabetes Mellitus (DM). 
Patients and Methods: Participants were selected from 
out-patient department of Sheikh Zayed Hospital, Lahore 
and Laboratory analysis was performed at department of 
chemical pathology, University of Health Sciences, Lahore. 
Total 60 patients of type-2 DM and 40 age and gender 
matched controls were included in study. Glycated 
haemoglobin (HbA1c), fasting blood glucose (FBG) and 
lipid profile was performed after overnight fasting. Control 
group was labelled as Group-A and patient group was 
labelled as Group-B. Mean of all parameters from both 
groups was compared and checked for significance by 
independent sample t-test and Pearson correlation.  
Results: There was no significant difference in mean values 
of all biochemical parameters between both genders, except 
total cholesterol, which was found higher in females (p-
value 0.047). Only 3.3% (n = 02) patients had normal lipid 
profile, 76.6% (n = 46) had one-abnormal parameter of lipid 
profile, 28.3% (n = 17) patients had two-abnormal 
parameter of lipid profile and 58.3% (n = 35) had mixed 
type of dyslipidemia. HbA1c was positively correlated with 
all parameters of lipid profile except HDL-C, which was 
negatively correlated.  
Conclusion: There is positive correlation between level of 
glycemic control (HbA1c) and severity of dyslipidemia in 
patients of type 2 DM.  
Key Words: Cardiovascular diseases, Diabetes mellitus 
type 2, Dyslipidemia, Glycated haemoglobin. 
Introduction 
Diabetes mellitus (DM) is cosmopolitan disease of the 
globe. DM is a group of metabolic disorders characterized 
by hyperglycemia either due to the lack of insulin secretion, 
or defects of insulin action or both.1 Recent reports showed 
that there were 171 million people in the world with diabetes 
in year 2000 and this is expected to increase to 366 million 
by 2030.2 It is associated with reduced life expectancy, 
significant morbidity due to specific diabetes related 
microvascular complications, increased risk of 
macrovascular complications (ischaemic heart disease, 
stroke and peripheral vascular disease), and lessened quality 
of life. 
Glycated haemoglobin (HbA1c) is usually used as a 
monitoring tool for measuring glycemic control in DM 
patients. It gives glycemic control status for last 120 days.3 
HbA1c predicts risk for development of diabetic 
complication in diabetic patients. United Kingdom 
Prospective Diabetes Study (UKPDS) has revealed that risk 
of diabetic complications was strongly associated with 
previous hyperglycemia. Good glycemic control with 
decreased level of HbA1c is likely to reduce risk of 
complications.4 Estimated risk of cardiovascular disease 
(CVD) has shown to be increased by 18% for each 1% 
increase in absolute HbA1c value in diabetics.5 
The chronic hyperglycemia can damage several body organs 
due to microvascular and macrovascular complications.6,7 
Macrovascular complications of diabetes include 
cardiovascular disease (CVD) such as stroke, which is the 
cause of death in 50% of diabetics.8,9 On the other hand, 
microvascular complications of diabetes include diabetic 
nephropathy, neuropathy, and retinopathy.10 Cardiovascular 
risk of diabetes increases further if diabetes is related with 
dyslipidemia. However, this risk can be reduced by good 
management and control of both hyperglycemia and 
dyslipidemia.11,12 
A few studies have previously tried to find relationship 
between HbA1c levels, fasting blood glucose (FBG) and 
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lipid profile. Some of these have shown that all parameters 
of lipid profile have significant association with glycemic 
control.13 On the other hand, some studies do not report 
significant correlation between glycemic control and 
parameters of lipid profile.14 Positive relationship between 
HbA1c and CVD has been demonstrated in non-diabetic 
subjects even within normal range of HbA1c.15,16 
These controversies motivated us to conduct this study, to 
find out correlation between glycemic control (HbA1c), FBG 
and different parameters of lipid profile in type 2 diabetic 
patients coming to out-patients department of endocrinology 
at Sheikh Zayed Hospital, Lahore. 
Patients and Methods 
Prior to the start of study ethical permission was obtained 
from ethical committee of the Sheikh Zayed Hospital, 
Lahore. Total 60 patients of type 2 DM for > 05 years with 
overnight fasting were recruited from Sheikh Zayed 
Hospital, Lahore. Patients with renal disease, thyroidal 
illness, history of alcohol intake and improper fasting were 
excluded from study. Total 40 age and gender matched 
controls without history of any acute or chronic illness were 
also included.  02ml fasting blood samples were obtained 
after signing informed consent from all participants for the 
measurement of HbA1c, FBG and Lipid profile. HbA1c, 
FBG and Lipid Profile were performed on Monza Chemistry 
Analyzer by using Randox reagent kits. The instrument was 
properly calibrated and quality control (QC) levels were also 
run along with patient sample. HbA1c was performed by 
affinity Chromomatography technique. Statistical analysis 
was performed by using IBM – SPSS version 21.0. 
Independent sample t-test (2-tailed) was used to compare 
mean of all parameters. Pearson’s correlation test was done 
to evaluate correlations of HbA1c with all other parameters. 
All values of different parameters were expressed using 
conventional units. p-value ≤ 0.05 was considered 
statistically significant. 
Results 
Among sixty patients, 66% (n = 40) were females and 
remaining 34% (n = 20) were males. Out of forty controls, 
47.5% (n = 19) were males and 52.5% (n = 21) were 
females. Mean age for patient group was 51.17±6.85 years 
(male=52.85+7.12 years and female= 50.32+6.63 years) and 
for controls mean age was 42.82+13.66 years (male 
=45.53+12.69 years and female = 40.38+14.35 years). The 
frequency of dyslipidemia in our study population was 98%. 
Only 02% showed normal lipid profile components. Most 
common type of dyslipidemia was increased levels of  low 
density lipoprotein cholesterol (LDL-C) (68.3%) followed 
by hyper-triglyceridemia (55%), hyper-cholesterolemia 
(46.7%) and decreased levels of high density lipoprotein 
cholesterol (HDL-C) (Figure-1). 





No-abnormal parameter of lipid profile
One-abnormal parameter of lipid
profile
Two-abnormal parameters of lipid
profile
>2-abnormal parameters of lipid profile
Figure-1: Frequency of Dyslipidemia in diabetic patients 
In patient group (group-B) mean values of TC 42.33mg/dl, 
VLDL-C 11.89mg/dl, LDL-C 93.49mg/dl, Triglyceride 
58.29mg/dl, HbA1c 4.56% and FBG 89.52mg/dl were higher 
than control group (Group-A). 
Mean age for males in total study population was 2.52 years 
higher than females. Mean levels (mg/dl) of VLDL-C, HDL-
C, LDL-C, TG, FBG and HbA1c (%) were relatively higher 
in females (Table-1). 
Table-1: Comparison of lipid profile parameters and 



































































*p-value≤0.05 is considered statistically significant 
We divided patient group (Group – B) further in to two sub-
groups as good glycemic control (GGC) group and poor 
glycemic control (PGC) group. In GGC group patients had 
level of HbA1c < 7% and in PGC patients had level of 
HbA1c > 7%. We compared mean levels of lipid profile 
between these two groups. Mean difference of FBG was 
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found 53.0 mg/dl higher in group PGC and this was found 
statistically significant (Table-2). 
Table-2: Biochemical Parameters categorize on the 
basis of HbA1c 
Parameters HbA1c< 7 
(GGC)   
(n=10) 
HbA1c> 7 






52.90±7.97 50.82±6.64 0.385 
TC  
(mg/dL) 
211.40±49.36 198.48±55.80 0.449 
VLDL-
C(mg/dL) 
32.80±13.88 36.90±21.20 0.561 
HDL-C 
(mg/dL) 
53.60±23.35 47.22±14.01 0.423 
LDL-C 
(mg/dL) 
124.80±46.43 116.42±53.48 0.646 
TG-C 
(mg/dL) 
175.90±67.32 180.90±95.00 0.875 
FBG-C 
(mg/dL) 
133.10±34.60 186.10±67.12 0.001* 
*p–value ≤0.05 is considered statistically significant, GGC: 
Good glycemic control, PGC: Poor glycemic control 
HbA1c was positively correlated with all components of 
lipid profile except HDL-C which showed negative 
correlation. FBG showed significant positive correlation 
with HbA1c (Table-3). 
Table 3: Correlation between HbA1c and all 




TC  (mg/dL) 0.082 0.532 
VLDL-C(mg/dL) 0.244 0.061 
HDL-C(mg/dL) -0.058 0.658 
LDL-C(mg/dL) 0.029 0.826 
TG (mg/dL) 0.173 0.187 
FBG (mg/dL) 0.396 0.002* 
*p-value ≤ 0.05 is considered statistically significant 
Discussion 
Despite many strategies for diagnosis and monitoring of 
DM, still this is a major challenge for public health around 
the globe. In conditions like uncontrolled DM the proportion 
of glycosylated haemoglobin increases substantially. This 
glycosylation of haemoglobin is result of non-enzymatic 
binding of haemoglobin A molecules with glucose which 
occurs only once during the life of single red blood cell. The 
levels of HbA1c reflect the degree of glycemic control for 
last 120 days. So this is being used for diagnosis and 
monitoring diabetic control as well. The diabetic 
dyslipidemia is connected with raised levels of triglycerides, 
LDL-C and decreased HDL-C.17 
In our study we evaluated correlation of HbA1c with 
dyslipidemia. In Group-B 98.0% patients showed significant 
dyslipidemia. High LDL-C is most common followed by 
hyper-triglyceridemia, Hyper-cholesterolemia and Low 
LDL-C. 
Al-alawi et al in 2014 reported high prevalence of 
hypercholesterolemia, hypertriglyceridemia, high LDL-C 
and low HDL-C. They revealed that increase LDL-C level is 
more frequent type of dyslipidemia.18 It is well known that 
high LDL-C and low HDL-C levels are risk factors for 
development of cardiovascular diseases. Insulin effects the 
liver apolipoprotein production which is responsible for 
enzymatic activity of lipoprotein lipase and cholesterol 
esters transport protein. All these factors collectively cause 
dyslipidemia in DM.19  
Hyper triglyceridemia can be due to alteration of lipoprotein 
in type- 2 DM. It is caused by hyperglycemia, insulin 
resistance which results in overproduction of VLDL-C, 
defective clearance of VLDL-C, decreased activity of 
lipoprotein lipase and decreased production of 
apolipoprotein B. Consumption of VLDL is altered which 
ultimately results in atherosclerosis. In type–2 DM, 
hyperglycemia increases the activity of hepatic lipase which 
leads to enhanced clearance of HDL-C while impaired 
catabolism of VLDL-C which causes decreased production 
of HDL-C.20 
In present study, diabetic patients (n = 60) were divided into 
two groups as GGC group which included only 10 patients 
and PGC group which contained 50 patients. Severity of 
dyslipidemia was higher in patients with increased levels of 
Glycated hemoglobin (HbA1c >7%). Elevated HbA1c and 
dyslipidemia are sovereign risk factors of cardiovascular 
diseases. Through improvement in glycemic control, one can 
markedly diminish risk of cardiovascular events in diabetics. 
It has been assessed that reducing HbA1c level by 0.2% 
could lower mortality by 10%.6 Khan et al reported that 
impact of glycemic control is directly related to the severity 
of dyslipidemia.21 
The dyslipidaemia in diabetic is frequent because insulin 
resistance or deficiency affects vital enzymes and lipid 
metabolism.22,23 It affects the following processes: 
apoprotein production, regulation of lipoprotein lipase, 
action of cholesteryl ester, transfer proteins and hepatic and 
peripheral actions of insulin.22 It has been suggested that 
composition of lipid particles in diabetic dyslipidaemia is 
more atherogenic than other types of dyslipidaemia. This 
means that even normal lipid concentrations might be more 
atherogenic in diabetic than in nondiabetic people.22,24,25 
Pearson correlation was observed between HbA1c and other 
components of lipid profile and FBG. A significant positive 
correlation was seen with FBG. Our findings were strongly 
matched with previous literature reports.26,27 We also found 
positive but non-significant correlations between HbA1c and 
cholesterol, triglycerides, LDL-C and VLDL-C in type-2 
diabetic patients. HDL-C was found negatively correlated 
with HbA1c. Previously many researchers have reported the 
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importance of HbA1C for controlling dyslipidemia in 
patients with type-2 DM.28,29 
Conclusion 
Positive but non-significant correlation is found between 
glycemic control and severity of dyslipidemia in patients 
with type-2 DM. Thus by maintaining a good glycemic 
control, risk for the development of dyslipidemia and 
cardiac diseases can be reduced. Further studies should be 
conducted on a larger scale to significantly explore the role 
of HbA1c in the development of dyslipidemia in type-2 
Diabetic patients. 
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